Trial reportJournal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology
Activity of the uptake-1 norepinephrine transporter as measured by I-123 MIBG in heart failure patients with a loss-of-function polymorphism of the presynaptic alpha2C-adrenergic receptor.
Trial report in Journal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03227393 (The Effect of Yoga on Cardiac Sympathetic Innervation Evaluated by I-123 mIBG), which is not on this map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
The Effect of Yoga on Cardiac Sympathetic Innervation Evaluated by I-123 mIBG
Who cites it
10 citing papers in PubMed, 22 citations in OpenAlex.
- Iodine-123 Metaiodobenzylguanidine (I-123 MIBG) in Clinical Applications: A Comprehensive Review.Pharmaceuticals (Basel, Switzerland) · 2024Review
- F-18 meta-fluorobenzylguanidine PET imaging of myocardial sympathetic innervation.Journal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology · 2022Article
- Adrenergic-pathway gene variants influence beta-blocker-related outcomes after acute coronary syndrome in a race-specific manner.Journal of the American College of Cardiology · 2012Article
- Genetic variation, β-blockers, and perioperative myocardial infarction.Anesthesiology · 2011Review
- Bucindolol: a pharmacogenomic perspective on its use in chronic heart failure.Clinical Medicine Insights. Cardiology · 2011Article
- Mechanisms of pharmacogenomic effects of genetic variation within the cardiac adrenergic network in heart failure.Molecular pharmacology · 2009Review
- Alpha-adrenoceptor gene variants and autonomic nervous system function in a young healthy Japanese population.Journal of human genetics · 2007Article
- Polymorphisms of cardiac presynaptic alpha2C adrenergic receptors: Diverse intragenic variability with haplotype-specific functional effects.Proceedings of the National Academy of Sciences of the United States of America · 2004Article
- A conceptual paradox of MIBG uptake in heart failure: retention with incontinence!Journal of nuclear cardiology : official publication of the American Society of Nuclear CardiologyArticle
- Cardiac receptor physiology and imaging: an update.Journal of nuclear cardiology : official publication of the American Society of Nuclear CardiologyArticle
Corrections and comments
- Commented on by
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPatients with a deletion of 4 consecutive amino acids in the gene encoding for the alpha(2C)-adrenergic receptor (alpha(2C)Del322-325) have an increased prevalence of clinical heart failure, worse clinical status, and a lower left ventricular ejection fraction compared with patients without this deletion. We postulated that patients with the alpha(2C)Del322-325 polymorphism would have a compensatory increase in norepinephrine uptake-1 transporter activity as measured by iodine 123 metaiodobenzylguanidine (MIBG). METHODS AND
resultsThirty-nine patients with heart failure related to idiopathic dilated cardiomyopathy were studied. Demographic characteristics, left ventricular ejection fraction, maximum oxygen consumption, exercise duration, and plasma norepinephrine levels did not differ between patients with the alpha(2C) receptor polymorphism (n = 9) and those without it (n = 30). Patients with the alpha(2C)Del322-325 polymorphism had significantly greater heart-to-mediastinum ratios of I-123 MIBG at 4 hours after tracer injection (1.60 +/- 0.19 vs 1.41 +/- 0.19, P =.0117) and greater background-corrected heart counts per pixel at 4 hours compared with patients without the polymorphism.
conclusionsPatients with genetic impairment of the alpha(2C)-adrenergic receptor have augmented activity of the norepinephrine uptake-1 transporter as measured by I-123 MIBG. Further studies are needed to clarify the mechanism by which uptake-1 transporter activity is increased in this setting.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.